First patient in Cohort four has been treated with TTX-MC138 Ten patients have been treated with TTX-MC138 at escalating dose levels Additional patients being evaluated ...

TransCode Therapeutics (RNAZ) announced that the first patient in Cohort 4 of its Phase I clinical trial has received their initial dose.

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the first patient in Cohort 4 of its ...

Regulus Therapeutics (RGLS) stock soars after positive Phase 1b trial data for the company's lead asset, farabursen against a ...

TransCode (NASDAQ: RNAZ) , the oncology company committed to utilizing RNA therapeutics to more effectively treat cancer, has announced the closing o ...

ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, announced today its participation in the 24th Annual ...

Fungal infections are on the rise globally. According to a study by the Manchester Fungal Infection Group, in 2022, ...

Cornell researchers have confirmed that a previously identified biomarker for detecting the presence of malignant testicular germ cell tumors has the potential to improve patient outcomes through ...

A DNA nanomachine selectively targets skin cancer by detecting microRNA-7, activating phototherapy and releasing chemotherapy ...

In a study published today in the ExRNA journal, researchers from the Novosibirsk Institute of Chemical Biology and Fundamental Medicine have proved that pre-analytical variables, as blood plasma or ...

The following is a summary of “Identification of hypertension subtypes using microRNA profiles and machine learning,” ...

NEW YORK – Cancer diagnostics firm AccuStem Sciences announced on Tuesday that it has acquired the license for the proprietary MicroRNA Signature Classifier (MSC) test for lung cancer screening from ...